The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Guardant360 CDx assay receives FDA approval as first liquid biopsy NGS companion diagnostic test

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Guardant360 CDx assay is the first liquid biopsy companion diagnostic test that uses next-generation sequencing technology to receive FDA approval. The assay uses NGS technology to identify patients with specific types of mutations of the epidermal growth factor receptor gene in a deadly form of metastatic non-small cell lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?
By McKenzie Prillaman
ClinicalTrials & Tribulations

A simple intervention could help address overlooked pain among older adults with cancer in rural America

A recent article in JAMA Network Open published by myself and my research collaborators—Jill Harrison at Brown University, Sarah Yarborough at Fred Hutch, and Tammy Stokes at Maury Regional Medical Center—examined the potential for a brief communication-based intervention to help older adults with cancer who live in rural settings better manage their pain. 
By Megan J. Shen
Table of Contents

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account